Assessment and Management of Urinary Dysfunction in 187 Patients with Parkinson's Disease

J Parkinsons Dis. 2020;10(3):993-1001. doi: 10.3233/JPD-191806.

Abstract

Background: Urinary dysfunction is common in Parkinson's disease (PD) patients and management options are limited.

Objective: This study aimed to explore the management of urinary dysfunction by researching the special needs of PD patients.

Methods: PD patients with urinary dysfunction who underwent urodynamic testing were recruited from a single center from October 2013 to February 2019. The urinary symptoms, International Prostate Symptom Score and Hoehn-Yahr scale were evaluated. Management was made at the urologists' discretion with follow-up after three weeks. Urinary symptoms, urodynamics and the management of urinary dysfunction were analyzed.

Results: A total of 187 patients with a median age of 66.2 and Hoehn-Yahr scale soccer of 2 were enrolled. Irritative symptoms were more common than obstructive symptoms, while obstructive symptoms were more common in male than female patients, except for incomplete voiding. There were 51% cases of detrusor overactivity, followed by 33% with bladder outlet obstruction, 13% had normal function, 12% had detrusor underactivity, 9% had stress incontinence, 7% had increased bladder sensation and 4% had an acontractile bladder. Tolterodine and tamsulosin were the most common therapeutic agents, respectively prescribed to 38.5% and 27.3% of the patients. Other treatments included catheterization, botulinum toxin A bladder wall injection, transurethral resection of the prostate and urethral dilatation. Urinary symptoms were improved significantly in 74.5% of the patients (p < 0.001), including 27 patients treated with tamsulosin only and 54 patients with tolterodine only.

Conclusions: Urinary symptoms and urodynamics were highly variable in PD patients, indicating that most patients may benefit from personalized management.

Keywords: Parkinson’s disease; management; urinary dysfunction; urodynamics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Botulinum Toxins, Type A / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Severity of Illness Index
  • Transurethral Resection of Prostate / methods
  • Urinary Bladder / metabolism
  • Urinary Bladder / physiopathology
  • Urinary Bladder, Overactive / drug therapy*
  • Urinary Bladder, Overactive / metabolism
  • Urination Disorders / drug therapy*
  • Urination Disorders / metabolism

Substances

  • Botulinum Toxins, Type A